- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Romney on Drug Prices; Kentucky Delays Work Requirements; Teva's Epinephrine Shortage
Senator Mitt Romney, R-Utah, warned PhRMA that he and his new colleagues are working to tackle the issue of high prescription drug prices; Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population; despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors.
Romney Tells PhRMA Changes in Drug Pricing Are Coming
Kentucky Delaying Start of Medicaid Work Rules
Teva's Epinephrine in Short Supply Months After Approval
Senator Mitt Romney, R-Utah, warned the Pharmaceutical Research and Manufacturers of America (PhRMA) that he and his new colleagues are working to tackle the issue of high prescription drug prices in a closed-door meeting, STAT News reported. The industry should be prepared to take part in participate in those discussions, he said.Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population, the Associated Press reported. A federal judge blocked the rules last year, but the Trump administration approved them a second time in November. Some of the rules were to start April 1, but they will now begin no sooner than July 1, the state said.Despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors, Reuters reported. The short supply means Teva cannot compete with Mylan in a roughly $750 million a year US market. Mylan’s EpiPen has also been in short supply since spring 2018. Teva did not say why its drug was in short supply.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
